Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
U2 small nuclear RNA is a highly conserved, non-coding RNA found in all eukaryotic cells, acting as a core catalytic RNA element within the major spliceosome[1][2]. It functions as part of the U2 small nuclear ribonucleoprotein (U2 snRNP) complex and is essential for pre-mRNA splicing; the U2 snRNA base pairs with the branch point sequence (BPS) of introns, positioning the branch adenosine for the first catalytic step of splicing, and forms critical RNA-RNA and RNA-protein contacts for spliceosome assembly and function[1][2][3]. U2 snRNA is heavily modified post-transcriptionally (including by pseudouridylation and 2′-O-methylation), and these modifications are vital for proper snRNP assembly and splicing function[4]. The dynamic rearrangement and RNA-protein interactions involving U2 snRNA are central to the conformational and catalytic activities of the spliceosome[7]. While not a direct therapeutic target like enzymes or receptors, disruption in U2 snRNA function or spliceosome assembly can cause global defects in gene expression and is implicated in disease through general splicing errors[1][2].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on U2 small nuclear RNA (U2 snRNA).